Dianthus Therapeutics (DNTH) director receives grant of 6,090 stock options

Rhea-AI Filing Summary

Dianthus Therapeutics director Alison Frances Lawton received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, she holds 6,090 stock options directly.

According to the grant terms, all shares underlying this option will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual meeting of stockholders, as long as she continues to serve the company through the vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lawton Alison Frances

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	6,090	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 6,090 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 6,090 options Exercise price: $89.63 per share Expiration date: May 21, 2036 +2 more

5 metrics

Options granted 6,090 options Stock option grant on May 21, 2026

Exercise price $89.63 per share Stock option exercise price

Expiration date May 21, 2036 Option expiration

Underlying shares 6,090 shares Common stock underlying options granted

Options held after grant 6,090 options Total derivative holdings following transaction

Key Terms

Stock Option (Right to Buy), exercise price, vesting, Annual Meeting of Stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 89.6300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares of common stock underlying this stock option award will vest in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting of Stockholders financial

"the Issuer's 2027 Annual Meeting of Stockholders"

continued service financial

"subject to the Reporting Person's continued service to the Issuer"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lawton Alison Frances

(Last) (First) (Middle)

C/O DIANTHUS THERAPEUTICS, INC.

7 TIMES SQUARE, 43RD FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$89.63	05/21/2026		A		6,090		(1)	05/21/2036	Common Stock	6,090	$0	6,090	D

Explanation of Responses:

1. The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.

	/s/ Adam Veness, as attorney-in-fact for Alison Frances Lawton	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Dianthus Therapeutics (DNTH) report for Alison Frances Lawton?

Dianthus Therapeutics reported that director Alison Frances Lawton received a stock option grant for 6,090 shares. These options give her the right to buy common stock at a fixed exercise price if vesting and other conditions are met.

How many stock options did Alison Frances Lawton receive from Dianthus Therapeutics (DNTH)?

She received stock options covering 6,090 shares of Dianthus Therapeutics common stock. This entire amount represents her direct derivative holdings following the transaction as reported in the Form 4 insider filing.

What is the exercise price of Alison Frances Lawton’s Dianthus Therapeutics (DNTH) stock options?

The exercise price of the options is $89.63 per share. This is the price at which she can purchase Dianthus Therapeutics common stock if the options vest and she chooses to exercise them before expiration.

When do Alison Frances Lawton’s Dianthus Therapeutics (DNTH) stock options vest?

The options vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual meeting. Vesting is contingent on her continued service to Dianthus Therapeutics through that vesting date.

When do Alison Frances Lawton’s Dianthus Therapeutics (DNTH) stock options expire?

The stock options expire on May 21, 2036. After this expiration date, she can no longer exercise the options to purchase Dianthus Therapeutics common stock, even if they previously vested.